Group 1 - The core viewpoint of the article highlights the positive impact of new policies on the medical industry, particularly in pathology services and medical equipment, which are expected to drive growth in the sector [1] - The medical industry ETF (159877.SZ) has seen a rise of 1.99%, with specific stocks like Lepu Medical increasing by 6.58%, indicating strong market interest [1] - The implementation of refined pricing policies for pathology services is set to standardize and digitize the sector, enhancing the value of digital technologies such as digital slicing and remote diagnosis [1] Group 2 - The government is expected to continue promoting medical equipment updates through 2026, focusing on optimizing application conditions and supporting small and medium-sized enterprises, which will likely boost the bidding environment for medical devices [1] - As company inventory levels clear, a turning point in industry performance is anticipated, with particularly strong demand for high-end medical equipment [1] - The dual policy benefits are expected to significantly benefit the medical industry ETF, especially in the areas of pathology diagnosis and high-end medical equipment [1]

Group 1 - The core viewpoint of the article highlights the positive performance of the healthcare sector, particularly in the fields of collagen and skincare products, with significant growth opportunities identified [1] - The Medical Industry ETF (159877.SZ) increased by 4.05%, and Lepu Medical surged by 19.99%, indicating strong market interest and investor confidence in the sector [1] - Jianghai Securities emphasizes the multi-dimensional investment logic in the healthcare industry, particularly in the collagen sector, where new entrants like Chuangjian Medical are gaining traction with their cross-linked collagen implants [1] Group 2 - The approval of cross-linked collagen products by Chuangjian Medical positions it as a strong competitor in the market, following the successes of Jinbo Biology and Juzhi Biology [1] - The "oil-based skincare" segment is projected to see sales exceeding 9.5 billion yuan from March 2024 to February 2025, reflecting a 36% growth, driven by advancements in domestic brands [1] - Continuous improvements in ingredients, technology, and formulations are enhancing industry standards, further propelling growth in the healthcare sector [1]